Three days. One window. I am still looking through it.

Have you heard the joke? Trump and a preacher enter a bar. Issue 10. Neither appears here as villain or hero — only as signal. Now — the window.

On Saturday, President Trump signed an executive order expediting federal approval of psychedelic treatments for mental illness. Ibogaine was named specifically; a plant-derived compound used in other countries for decades to treat PTSD, now moving toward the center of American medicine.

The next morning was Sunday. I was in an Uber on the way to the airport to fly back to Los Angeles. The driver had the radio on. A preacher was speaking.

He was talking about meditation and psychedelics and how both of these things are not of God.

My first instinct was to ask the driver to change the station. I stopped myself. I became curious instead. I wanted to hear the whole perspective, not just the part that confirmed what I already believe.

I listened. My position did not change. What changed was my understanding of how wide the gap is.

The preacher said this: coming from the heart is not of God. Our job, he said, is to stay in the head. The head is where we get closer to God.

I sat with that for the rest of the drive.

Everything Signal Edge is built on sits on the opposite side of that sentence. The heart as signal. The body as intelligence. The inner life as data. The idea that getting quieter, going deeper and moving toward sensation and feeling and intuition rather than away from it; this is where the real information lives.

I am not interested in arguing with the preacher. I am interested in the fact that the same 72-hour window held both his world and mine. A federal executive order on psychedelic medicine. A Sunday sermon on the danger of the heart.

The signal is always in the collision. The edge is where two things that have never touched each other suddenly occupy the same space.

I am living my life in a place of allowing, of presence and softness. That space is where I feel most myself. Rigidity and the need to be right are moving further from me, and the distance feels like freedom. I brought this window to you from that place. You will draw your own conclusions. That is exactly what I want for you.

This is not a trend. It is a threshold.

Psychedelic medicine has been moving in one direction for a decade. The research has been careful and rigorous. The clinical results have been hard to dismiss. Veterans groups have been traveling to clinics in Mexico because the treatments that were helping them were not yet available at home. That gap is now closing.

The executive order is one piece of it; the FDA has also announced priority review vouchers for three psychedelic treatments in the same week. Deutsche Bank and Morgan Stanley have both initiated coverage of psychedelic biotech companies. Institutional money does not move early. It moves when the direction is clear.

Here is what this means for you right now.

If someone in your life is living with treatment-resistant depression, PTSD, or addiction that has not responded to anything else; this is a category worth understanding. The clinical results are specific and meaningful. A single guided session of psilocybin has produced measurable changes in the brain’s default mode network, the system associated with rumination and the fixed stories we carry about who we are. Patients describe a loosening of those stories. Ibogaine has interrupted addiction pathways in a single extended session, with results that last months. These are outcomes that conventional pharmacology has not consistently produced.

You do not have to have a personal connection to this to pay attention. The investment case is real and the healthcare case is real and they are both worth following.

If you are curious about where this goes; watch the companies in the Signal Stack section below, watch the FDA approval timeline for MDMA-assisted therapy and psilocybin, and watch whether ketamine’s Spravato sales trajectory holds. Spravato is the proof of concept. Two billion dollars in projected sales from an approved ketamine derivative is what institutional money needed to see.

The window is open. You do not have to walk through it today. You do have to know it is there.

What the compounds actually do.

The substances moving through federal approval now are specific and studied and meaningful in ways that most media coverage does not convey.

Ibogaine is derived from the iboga plant, native to Central Africa and used in other countries for decades to treat opioid addiction and PTSD. The mechanism is specific; ibogaine appears to interrupt addiction pathways in the brain in a single extended session, with results that last months. Veterans groups have been among its most vocal advocates, traveling to clinics in Mexico and elsewhere because the treatment was unavailable at home. That is changing now.

Psilocybin, derived from mushrooms, has shown significant results in clinical trials for treatment-resistant depression. A single guided session produces measurable changes in the brain’s default mode network; the system associated with rumination, self-referential thinking and the fixed stories we carry about who we are. Patients describe a loosening of those stories. A temporary but profound shift in perspective that many report as lasting.

Ketamine is already approved, in its esketamine form as Spravato; a nasal spray sold by Johnson and Johnson for treatment-resistant depression, projected to generate two billion dollars in sales this year. Ketamine opened the door. The compounds behind it are walking through it now.

What all of these treatments share: they are administered in clinical settings, with practitioners present and over extended sessions. They are experiences, not just medications. The container matters as much as the compound. That distinction is what makes them unlike anything currently in the pharmacological toolkit.

The preacher’s concern, if I am being generous, may be exactly this; these treatments ask you to go somewhere inside yourself that most Western medicine has never asked you to go. He calls that dangerous. The research calls it therapeutic.

Signal Edge calls it a signal worth understanding.

Position sizing for a category that just changed.

The investment landscape in psychedelic medicine shifted this week in ways that deserve a clear-eyed look.

For most of their existence, psychedelic biotechs have been retail investor territory; small companies, no revenue, long timelines and a federal government that classified their core compounds as dangerous controlled substances. Institutional money stayed away.

That is changing in real time.

Deutsche Bank and Morgan Stanley have both initiated coverage of psychedelic biotechs in recent months. The FDA has announced priority review vouchers for three treatments in the same week as the executive order. Priority review is not approval; it is the FDA saying we will move faster on this. That acceleration changes the timeline for every company in the category.

Here is how I think about position sizing in early-stage biotech categories like this one.

This is not a set-and-forget investment. The clinical timelines are long, the regulatory pathway is friendlier now but still complex and any one company’s results can move the whole category. The way to build exposure here is through a basket; either an ETF that holds multiple companies and gives you category exposure without company-specific concentration risk, or a small position in two or three of the leading names with the understanding that you are buying the category thesis, not a specific outcome.

The AdvisorShares Psychedelics ETF (PSIL) is the cleaner entry point for most investors; broader coverage, lower concentration risk and exposure to the companies below and others like them.

For individual names; Compass Pathways is the furthest along in clinical development for psilocybin-based treatment of treatment-resistant depression. Psyence Biomedical is focused on psilocybin for adjustment disorder in palliative care patients, a specific and focused application with a clear patient population. GH Research is working with 5-MeO-DMT, derived from the Sonoran Desert toad, for major depressive disorder; early stage with a compound profile generating significant scientific interest.

The Spravato benchmark is the number to hold in mind. Two billion dollars in projected sales from an approved ketamine derivative this year. That is what the category can become when a compound crosses the approval threshold. The question for the companies above is which one gets there next and when.

Position accordingly. Size for the possibility, not the certainty.

Nothing in this section is financial advice. It is pattern recognition. Do your own research and consult a financial professional before making investment decisions.

The companies and the category.

The signal I did not plan to receive that Sunday.

I planned to sleep on the way to the airport.

Instead I sat in the back of an Uber at seven in the morning with the radio on and a preacher telling me that the heart is where we go wrong. That the head is where we find God. That meditation and psychedelics are the same kind of danger; the danger of going inward, of loosening the grip of the analytical mind, of trusting anything that bypasses reason on its way to wherever it is going.

I run a logistics company. I built Santosa Delivery from a contract received in July 2018. I live between three cities and I write a newsletter and I run on most mornings and I have spent the last several years learning, slowly and with difficulty, how to trust what the heart sends before the head has finished analyzing it.

The preacher was making an argument I have heard in different forms my whole life. Stay in the head. The head is safe. The head is where control lives.

Signal Edge exists because I stopped believing that.

The heart as signal. The body as intelligence. The inner life as data that deserves the same rigor and attention we give to balance sheets and clinical trials. I built this community on that premise and I have watched it work in the lives of the women reading this; in the threads they pull and the places those threads take them, in the small yeses that turn into something they could never have planned their way to.

The 72-hour window that held the executive order and the Sunday sermon and the Uber driver’s radio is still open in my mind. I am glad I did not ask him to change the station.

That is the signal. The one you almost turn off is sometimes the most important one to hear all the way through.

Head versus heart. This is the whole argument.

The preacher was making a specific theological claim: the head is the seat of the divine. The heart is where we go astray.

That argument is older than the sermon. It runs through centuries of Western religious thought, through the elevation of reason over sensation and through the suspicion of mysticism, of ecstasy and of any experience that bypasses the analytical mind and arrives somewhere else first.

Signal Edge has been making the opposite argument since Issue 1.

Psychedelic-assisted therapy is not asking patients to abandon reason. It is asking them to temporarily loosen the grip of the default mode network; the analytical, self-referential mind, long enough to receive information that the analytical mind has been blocking. Then it asks them to integrate that information with the full capacity of their intelligence.

That is not anti-intellectual. That is the most demanding kind of knowing there is.

The preacher and I are not going to find common ground on this. I knew that by the time we reached the airport. What I found instead was clarity about what I believe and why Signal Edge exists.

We are building lives from the inside out. We are treating the inner signal as real. We are investing in the instruments that help us hear it more clearly.

The window was open for three days. I brought you to it. What you do with it from here is yours.

Stay curious. Stay in charge.